Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Long-Term Deferred Tax of $117.0 million for Q1 2026, down 7.16% on a QoQ basis from $126.0 million in Q4 2025, and up 9.08% year-over-year from $107.2 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $117.0 million for Q1 2026.
- Quarterly Long-Term Deferred Tax rose 9.08% year-over-year to $117.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.0 million (up 9.08% YoY) and the FY2025 annual result came in at $126.0 million, up 7.8% from the prior year.
- Long-Term Deferred Tax was $117.0 million for Q1 2026 at Alnylam Pharmaceuticals, down from $126.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
- A 4-year average of $97.1 million and a median of $107.2 million in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax jumped 1056.94% — and 2025, when it gained 7.8%.
- Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then advanced by 7.8% to $126.0 million in 2025, then decreased by 7.16% to $117.0 million in 2026.
- Business Quant data shows ALNY's Long-Term Deferred Tax at $117.0 million in Q1 2026, $126.0 million in Q4 2025, and $98.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.96 Mn |
| Dec 31, 2025 | 125.98 Mn |
| Sep 30, 2025 | 98.56 Mn |
| Jun 30, 2025 | 104.36 Mn |
| Mar 31, 2025 | 107.22 Mn |
| Dec 31, 2024 | 116.86 Mn |
| Dec 31, 2023 | 10.10 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Sep 30, 2010 | 8.57 Mn |
| Jun 30, 2010 | 8.67 Mn |
| Dec 31, 2009 | 8.56 Mn |